Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47.
Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16(1):130.
Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, et al. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J. 2018;48(2):144–51.
Polanco-Briceno S, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res Notes. 2016;9:157.
van Asten M, Verhaegh P, Koek G, Verbeek J. The increasing burden of NAFLD fibrosis in the general population: time to bridge the gap between hepatologists and primary care. Hepatology. 2017;65(3):1078.
Bergram M, Nasr P, Iredahl F, Kechagias S, Rådholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish primary health care. Scand J Gastroenterol. 2021;(1):10. https://doi.org/10.1080/00365521.2021.1984572.
Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56(3):943–51.
Nationella Diabetesregistret årsrapport. 2023: The Swedish National Diabetes Register; 2024. Available from: https://ndr.registercentrum.se. Accessed 2025-10-15.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.
Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–44.
Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. J Clin Med. 2022. https://doi.org/10.3390/jcm11040968.
Mikolasevic I, Rahelic D, Turk-Wensween T, Ruzic A, Domislovic V, Hauser G, et al. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: a multicenter study. Diabetes Res Clin Pract. 2021;177:108884.
Song D, Li C, Wang Z, Zhao Y, Shen B, Zhao W. Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: a meta-analysis of observational studies. J Diabetes Investig. 2021;12(8):1471–9.
Afarideh M, Aryan Z, Ghajar A, Ganji M, Ghaemi F, Saadat M, et al. Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Prim Care Diabetes. 2019;13(6):505–14.
de Lédinghen V, Vergniol J, Gonzalez C, Foucher J, Maury E, Chemineau L, et al. Screening for liver fibrosis by using FibroScan(®) and fibrotest in patients with diabetes. Dig Liver Dis. 2012;44(5):413–8.
Zhang L, Lin Y, Huang X, Zhai Z, Wei R, Mo J, et al. Metabolic dysfunction-associated fatty liver disease in the elderly with diabetic foot ulcers: a longitudinal cohort study. Int Wound J. 2024;21(4):e14586.
Huang X, Li Z, Zhai Z, Wang Q, Wei R, Mo J, et al. Association between metabolic Dysfunction-Associated fatty liver disease and MACCEs in patients with diabetic foot ulcers: an ambispective longitudinal cohort study. Diabetes Metab Syndr Obes. 2024;17:1119–30.
Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156–62.
Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64–76.
Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006–16.
Definition. and Diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva, Switzerland: World Health Organization; 2006.
WHO Guidelines Approved by the Guidelines Review Committee. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization. Copyright © World Health Organization 2011.; 2011.
Nasr P, Iredahl F, Dahlström N, Rådholm K, Henriksson P, Cedersund G, et al. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol. 2021;21(1):180.
Gastroenterology SSo. Nationell riktlinje – Utredning och handläggning av fettleversjukdom 2020 [Swedish guidelines for NAFLD]. Available from: https://svenskgastroenterologi.se/wp-content/uploads/2020/02/2020-utredning-och-handlaggning-av-fettleversjukdom.pdf. Accessed 2025-10-15.
Bedossa P. Utility and appropriateness of the fatty liver Inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–75.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.
EASL-EASD-EASO Clinical. Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542.
Skinner HA, Sheu WJ. Reliability of alcohol use indices. The lifetime drinking history and the MAST. J Stud Alcohol. 1982;43(11):1157–70.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.
van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology. 2013;57(6):2180–8.
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100.
Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–82.
Shen TH, Wu CH, Lee YW, Chang CC. Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12–79 years. Eur J Gastroenterol Hepatol. 2024;36(5):636–45.
Nanayakkara N, Ranasinha S, Gadowski A, Heritier S, Flack JR, Wischer N, et al. Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes. J Diabetes Complications. 2018;32(3):279–90.
Miller KC, Geyer B, Alexopoulos AS, Moylan CA, Pagidipati N. Disparities in metabolic dysfunction-associated steatotic liver disease prevalence, diagnosis, treatment, and outcomes: a narrative review. Dig Dis Sci. 2025;70(1):154–67.
Singh SS, van Roeters-Lennep JE, Lemmers RFH, van Herpt TTW, Lieverse AG, Sijbrands EJG. Sex difference in the incidence of microvascular complications in patients with type 2 diabetes mellitus: a prospective cohort study. Acta Diabetol. 2020;57(6):725–32.
Martínez-Sánchez FD, Corredor-Nassar MJ, Feria-Agudelo SM, Paz-Zarza VM, Martinez-Perez C, Diaz-Jarquin A, et al. Factors associated with advanced liver fibrosis in a population with type 2 diabetes: a multicentric study in Mexico City. J Clin Exp Hepatol. 2025;15(4):102536.
Yang K, Lee J, Han JW, Yang H, Chae SY, Chung BS, et al. A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases. Ther Adv Gastroenterol. 2025;18:17562848251331315.
Park SK, Kim MH, Jung JY, Oh CM, Ha E, Nam DJ, et al. Changes in smoking status, amount of smoking and their relation to the risk of microvascular complications in men with diabetes mellitus. Diabetes Metab Res Rev. 2023;39(8):e3697.
Balkhed W, Bergram M, Iredahl F, Holmberg M, Edin C, Carlhäll CJ, et al. Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care. J Intern Med. 2025. https://doi.org/10.1111/joim.20103.
Gao S, Zhang H, Long C, Xing Z. Association between obesity and microvascular diseases in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2021;12:719515.
Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. Front Med. 2025;12:1539283.
Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128(12):1325–34.
Ma XM, Guo YM, Jiang SY, Li KX, Zheng YF, Guo XG, et al. Potential predictive role of non-HDL to HDL cholesterol ratio (NHHR) in MASLD: focus on obese and type 2 diabetic populations. BMC Gastroenterol. 2025;25(1):79.
Han M, Shen Y, Guo X, Hong C, Ji X, Guo H, et al. Association between non-high-density lipoprotein cholesterol and type 2 diabetes: a systematic review and meta-analysis of cohort studies. Endocr J. 2025;72(1):43–51.
Baek SU, Yoon JH, High-Sensitivity C-R. Protein levels in metabolic dysfunction-Associated steatotic liver disease (MASLD), metabolic Alcohol-Associated liver disease (MetALD), and alcoholic liver disease (ALD) with metabolic dysfunction. Biomolecules. 2024;14(11):1486.
Tang M, Cao H, Wei XH, Zhen Q, Liu F, Wang YF, et al. Association between high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:885516.
Vaz J, Nasr P, Helander A, Shang Y, Wester A, Strandberg R, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025. https://doi.org/10.1016/j.jhep.2025.04.019.
Elgendy R, Deschênes SS, Burns RJ, Levy M, Schmitz N. Alcohol consumption, depressive symptoms, and the incidence of diabetes-related complications. J Diabetes. 2019;11(1):14–22.
Perazza F, Leoni L, Colosimo S, Musio A, Bocedi G, D’Avino M, et al. Metformin and the liver: unlocking the full therapeutic potential. Metabolites. 2024. https://doi.org/10.3390/metabo14040186.
Bahardoust M, Mehrabi Y, Hadaegh F, Azizi F, Khalili D, Delpisheh A. The association between duration of Metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis. J Diabetes Metab Disord. 2025;24(1):94.
Wang MW, Lu LG. Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective. J Clin Transl Hepatol. 2025;13(1):47–61.
Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933–41.
Jingi AM, Noubiap JJ, Essouma M, Bigna JJ, Nansseu JR, Ellong A, et al. Association of insulin treatment versus oral hypoglycaemic agents with diabetic retinopathy and its severity in type 2 diabetes patients in Cameroon, sub-Saharan Africa. Ann Transl Med. 2016;4(20):395.
Yan LH, Mu B, Guan Y, Liu X, Zhao N, Pan D, et al. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications. J Diabetes Investig. 2016;7(6):889–94.
Adrian T, Hornum M, Knop FK, Almdal T, Rossing P. Nonalcoholic fatty liver disease in patients with type 2 diabetes and chronic kidney disease. Nephron. 2023;147(6):317–28.
Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015;7(4):638–48.
Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, et al. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. J Diabetes Complications. 2015;29(8):1240–7.
Kim K, Oh TJ, Cho HC, Lee YK, Ahn CH, Koo BK, et al. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep. 2021;11(1):24372.
Käräjämäki AJ, Hukkanen J, Ukkola O. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. Ann Med. 2018;50(5):371–80.
Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471–8.
Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Mossialos E, et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int. 2024;44(1):61–71.
Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31(5):700–6.
Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care. 2015;38(7):1347–55.
Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, et al. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2015;3:141–5.
National Board of Health and Welfare. Nationella riktlinjer för diabetesvård [Swedish guidelines for diabetes 2018]. Available from: https://www.socialstyrelsen.se/publikationer/nationella-riktlinjer-for-diabetesvard–stod-for-styrning-och-ledning-2018-10-25/. Accessed 2025-10-15.
Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol. 2025;23(1):103–13.